Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following ...
Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $1.3 which represents a slight increase of $0.17 or 15.04% from the prior close of $1.13. The stock opened at $1.13 and ...
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...
Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, terminated its global collaboration and license agreement for giroctocogene ...